Rankings
▼
Calendar
TGTX FY 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$616M
+87.3% YoY
Gross Profit
$515M
83.6% margin
Operating Income
$123M
20.0% margin
Net Income
$447M
72.6% margin
EPS (Diluted)
$2.77
Cash Flow
Operating Cash Flow
-$25M
Free Cash Flow
-$25M
Stock-Based Comp.
$65M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$415M
Stockholders' Equity
$648M
Cash & Equivalents
$79M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$616M
$329M
+87.3%
Gross Profit
$515M
$291M
+77.4%
Operating Income
$123M
$42M
+194.1%
Net Income
$447M
$23M
+1812.4%
← Q4 2024
All Quarters
Q1 2025 →